Novo Nordisk warns consumers about counterfeit 1 mg dose of Ozempic in the U.S.
April 14 (Reuters) - Novo Nordisk NOVOb.CO said on Monday it has become aware of several hundred units of counterfeit 1 mg dose of its diabetes drug Ozempic being distributed outside its authorized supply chain in the United States.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Microsoft 2026 Q3 Earnings Preview: Can Azure’s Growth Momentum Keep Up With Massive AI Capital Spending?

Marvell vs. Broadcom: Who Is the More Worthy ASIC Leading Company?

Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

Meta Earnings Preview: AI Advertising Drives Growth, $100 Billion Spending Tests Margins

Tradingkey








